Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma
BackgroundTo systematically identify the long-term efficacy of postoperative adjuvant hepatic artery infusion chemotherapy (HAIC) for patients with hepatocellular carcinoma (HCC).MethodsPubMed, MedLine, Embase, the Cochrane Library, and Web of Science were searched to collect the eligible studies up...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.720079/full |
| _version_ | 1819320186349551616 |
|---|---|
| author | Qiao Ke Qiao Ke Lei Wang Weimin Wu Xinhui Huang Ling Li Jingfeng Liu Jingfeng Liu Wuhua Guo |
| author_facet | Qiao Ke Qiao Ke Lei Wang Weimin Wu Xinhui Huang Ling Li Jingfeng Liu Jingfeng Liu Wuhua Guo |
| author_sort | Qiao Ke |
| collection | DOAJ |
| description | BackgroundTo systematically identify the long-term efficacy of postoperative adjuvant hepatic artery infusion chemotherapy (HAIC) for patients with hepatocellular carcinoma (HCC).MethodsPubMed, MedLine, Embase, the Cochrane Library, and Web of Science were searched to collect the eligible studies up to March 31, 2021, that compared the surgical resection (SR) versus SR+HAIC for HCC patients. The endpoints were overall survival (OS) rates and disease-free survival (DFS) rates, and the effect size was determined by hazard ratio (HR) with 95% CI.ResultsA total of 12 studies (two randomized controlled trials (RCTs) and 10 non-RCTs) including 1,333 patients were eligible for this meta-analysis. The pooled results showed that OS and DFS rates in the SR+HAIC group were both better than those in the SR alone group (HR = 0.56, 95% CI = 0.41–0.77, p < 0.001; HR = 0.66, 95% CI = 0.55–0.78, p < 0.001, respectively). Furthermore, the subgroup analysis showed that patients would benefit from SR+HAIC regardless of chemotherapy regimens and courses (all p < 0.05), and patients with microvascular or macrovascular invasion would also benefit more from SR+HAIC in terms of OS and DFS (all p < 0.05).ConclusionPostoperative adjuvant HAIC could improve the long-term prognosis of HCC patients, especially for those with microvascular or macrovascular invasion, regardless of chemotherapy regimens and courses, but it deserves further validation. |
| first_indexed | 2024-12-24T11:15:35Z |
| format | Article |
| id | doaj.art-360d1cae332042faaa12fc61a8f1e74d |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-24T11:15:35Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-360d1cae332042faaa12fc61a8f1e74d2022-12-21T16:58:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-12-011110.3389/fonc.2021.720079720079Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular CarcinomaQiao Ke0Qiao Ke1Lei Wang2Weimin Wu3Xinhui Huang4Ling Li5Jingfeng Liu6Jingfeng Liu7Wuhua Guo8Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Hepatopancreatobiliary Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, ChinaDepartment of Radiation Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, ChinaDepartment of Interventional Radiology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Interventional Radiology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Interventional Radiology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Hepatopancreatobiliary Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, ChinaThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Interventional Radiology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, ChinaBackgroundTo systematically identify the long-term efficacy of postoperative adjuvant hepatic artery infusion chemotherapy (HAIC) for patients with hepatocellular carcinoma (HCC).MethodsPubMed, MedLine, Embase, the Cochrane Library, and Web of Science were searched to collect the eligible studies up to March 31, 2021, that compared the surgical resection (SR) versus SR+HAIC for HCC patients. The endpoints were overall survival (OS) rates and disease-free survival (DFS) rates, and the effect size was determined by hazard ratio (HR) with 95% CI.ResultsA total of 12 studies (two randomized controlled trials (RCTs) and 10 non-RCTs) including 1,333 patients were eligible for this meta-analysis. The pooled results showed that OS and DFS rates in the SR+HAIC group were both better than those in the SR alone group (HR = 0.56, 95% CI = 0.41–0.77, p < 0.001; HR = 0.66, 95% CI = 0.55–0.78, p < 0.001, respectively). Furthermore, the subgroup analysis showed that patients would benefit from SR+HAIC regardless of chemotherapy regimens and courses (all p < 0.05), and patients with microvascular or macrovascular invasion would also benefit more from SR+HAIC in terms of OS and DFS (all p < 0.05).ConclusionPostoperative adjuvant HAIC could improve the long-term prognosis of HCC patients, especially for those with microvascular or macrovascular invasion, regardless of chemotherapy regimens and courses, but it deserves further validation.https://www.frontiersin.org/articles/10.3389/fonc.2021.720079/fullhepatocellular carcinomahepatic artery infusion chemotherapysurgical resectionoverall survivaldisease-free survivalmeta-analysis |
| spellingShingle | Qiao Ke Qiao Ke Lei Wang Weimin Wu Xinhui Huang Ling Li Jingfeng Liu Jingfeng Liu Wuhua Guo Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma Frontiers in Oncology hepatocellular carcinoma hepatic artery infusion chemotherapy surgical resection overall survival disease-free survival meta-analysis |
| title | Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma |
| title_full | Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma |
| title_fullStr | Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma |
| title_full_unstemmed | Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma |
| title_short | Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma |
| title_sort | meta analysis of postoperative adjuvant hepatic artery infusion chemotherapy versus surgical resection alone for hepatocellular carcinoma |
| topic | hepatocellular carcinoma hepatic artery infusion chemotherapy surgical resection overall survival disease-free survival meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.720079/full |
| work_keys_str_mv | AT qiaoke metaanalysisofpostoperativeadjuvanthepaticarteryinfusionchemotherapyversussurgicalresectionaloneforhepatocellularcarcinoma AT qiaoke metaanalysisofpostoperativeadjuvanthepaticarteryinfusionchemotherapyversussurgicalresectionaloneforhepatocellularcarcinoma AT leiwang metaanalysisofpostoperativeadjuvanthepaticarteryinfusionchemotherapyversussurgicalresectionaloneforhepatocellularcarcinoma AT weiminwu metaanalysisofpostoperativeadjuvanthepaticarteryinfusionchemotherapyversussurgicalresectionaloneforhepatocellularcarcinoma AT xinhuihuang metaanalysisofpostoperativeadjuvanthepaticarteryinfusionchemotherapyversussurgicalresectionaloneforhepatocellularcarcinoma AT lingli metaanalysisofpostoperativeadjuvanthepaticarteryinfusionchemotherapyversussurgicalresectionaloneforhepatocellularcarcinoma AT jingfengliu metaanalysisofpostoperativeadjuvanthepaticarteryinfusionchemotherapyversussurgicalresectionaloneforhepatocellularcarcinoma AT jingfengliu metaanalysisofpostoperativeadjuvanthepaticarteryinfusionchemotherapyversussurgicalresectionaloneforhepatocellularcarcinoma AT wuhuaguo metaanalysisofpostoperativeadjuvanthepaticarteryinfusionchemotherapyversussurgicalresectionaloneforhepatocellularcarcinoma |